[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ceribell Inc (CBLL)

Ceribell Inc (CBLL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 955,228
  • Shares Outstanding, K 38,378
  • Annual Sales, $ 89,060 K
  • Annual Income, $ -53,410 K
  • EBIT $ -70 M
  • EBITDA $ -70 M
  • 60-Month Beta 0.81
  • Price/Sales 10.43
  • Price/Cash Flow N/A
  • Price/Book 7.16

Options Overview Details

View History
  • Implied Volatility 67.81% (+8.74%)
  • Historical Volatility 53.48%
  • IV Percentile 4%
  • IV Rank 5.83%
  • IV High 208.93% on 10/15/25
  • IV Low 59.07% on 08/17/26
  • Expected Move (DTE 1) 0.00 (0.00%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 2
  • Volume Avg (30-Day) 66
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 838
  • Open Int (30-Day) 639
  • Expected Range 24.31 to 24.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.50
  • Number of Estimates 4
  • High Estimate $-0.45
  • Low Estimate $-0.55
  • Prior Year $-0.37
  • Growth Rate Est. (year over year) -35.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.96 +52.32%
on 07/23/26
25.33 -4.03%
on 08/19/26
+5.88 (+31.90%)
since 07/20/26
3-Month
15.96 +52.32%
on 07/23/26
25.33 -4.03%
on 08/19/26
+6.21 (+34.31%)
since 05/20/26
52-Week
10.85 +124.06%
on 11/04/25
25.33 -4.03%
on 08/19/26
+12.73 (+109.93%)
since 08/20/25

Most Recent Stories

More News
Ceribell Reports Second Quarter 2026 Financial Results

SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with...

CBLL : 24.31 (-2.33%)
Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review

SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management...

CBLL : 24.31 (-2.33%)
Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System

SUNNYVALE, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management...

CBLL : 24.31 (-2.33%)
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe

SUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with...

CBLL : 24.31 (-2.33%)
Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference

SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with...

CBLL : 24.31 (-2.33%)
Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026

SUNNYVALE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with...

CBLL : 24.31 (-2.33%)
Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes

SUNNYVALE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with...

CBLL : 24.31 (-2.33%)
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference

SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with...

CBLL : 24.31 (-2.33%)
CeriBell Sees ‘Early Innings’ Growth as Hospital Accounts and Usage Hit Records

CeriBell (NASDAQ:CBLL) executives said the company’s first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining...

CBLL : 24.31 (-2.33%)
CeriBell Q1 Earnings Call Highlights

CeriBell (NASDAQ:CBLL) reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company’s strongest quarter...

CBLL : 24.31 (-2.33%)

Business Summary

CeriBell Inc. is a commercial-stage medical technology company. It focused on transforming the diagnosis and management of patients with serious neurological conditions. The company is an AI-powered, rapidly deployable point-of-care electroencephalography platform designed to address the unmet needs...

See More

Key Turning Points

3rd Resistance Point 25.64
2nd Resistance Point 25.31
1st Resistance Point 24.81
Last Price 24.31
1st Support Level 23.98
2nd Support Level 23.65
3rd Support Level 23.15

See More

52-Week High 25.33
Last Price 24.31
Fibonacci 61.8% 19.80
Fibonacci 50% 18.09
Fibonacci 38.2% 16.38
52-Week Low 10.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.